Softhale NV, a pharmaceutical company leveraging its respiratory soft mist inhalation platform to develop and commercialise COPD and asthma treatment products, announced yesterday that it has named Nevan Charles Elam, JD, as its new director effective October 2018.

Presently, Elam is the CEO and chairman of Rezolute Inc and he also serves on the board of directors of Savara Pharmaceuticals (NASDAQ: SVRA) in Austin, Texas. Earlier, he served for many years on the board of directors of Aerogen Inc in Galway, Ireland. He was SVP and head of the Pulmonary Business Unit at Nektar Therapeutics (NASDAQ: NKTR). During his tenure at Nektar he led the spin out of Pearl Therapeutics to focus on treatments for asthma and COPD.

Frank Pieters, chairman of the board, said, 'We are delighted to welcome Nevan on our board. His rich background in management, operations, consulting, finance, and corporate law in combination with long term experiences in executive roles in pharmaceutical and medical device companies will broaden the competencies of our board and support further development of the company.'